Traditionally, one of the major issues with commercializing cell therapy products has been manufacturing bottlenecks. The heterogeneous nature of cell therapy products has introduced manufacturing complexity and regulatory concerns, as well as scale-up complexities that are not present within traditional pharmaceutical manufacturing. Furthermore, much of cell therapy manufacturing now involves patient-specific cell therapies, where cells for an individual patient are processed one batch at a time.
Previously, it was believed that making individual batches of a therapy for a patient would never be a successful commercial model. It was assumed that allogeneic therapies would prevail, because universal cell populations could be prepared in advance to later be prescribed to patients, similar to how drug compounds are administered. Nonetheless, clinical data in support of patient-specific therapy has been compelling, so the pressure is on for the cell therapy industry to manufacture these therapies on a larger scale. Clearly, there are opportunities for the development of both autologous and allogeneic cell therapies, which vary greatly in their manufacturing requirements, routes for patient administration, and cost structures.
While many factors contribute to high pricing associated with cell therapies, a critical factor affecting the pricing of a cell therapy product is the cost of continuously manufacturing the product. To keep a cell therapy product “on market,” manufacturing costs of must be covered and a profit margin achieved. Therefore, great consideration must be given to the variables affecting the costs of goods (COGs) associated with cell therapy manufacturing, as well as strategies for process optimization.
Among cell therapy companies, the pressure for manufacturing process innovation can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise in cell therapy development and manufacturing, such as cell therapy contract and development manufacturing organizations (CDMOs).
Currently, there are more than 20 cell therapy CDMO’s specializing in manufacturing and clinical trial support for cell therapy companies, including: WuXi PharmaTech (and its subsidiary WuXi AppTec), Lonza Group, PCT (a Caladrius company), MEDINET, Cell and Gene Therapy Catapult, Brammer Bio, KBI Biopharmaceuticals, PharmaCell, Roslin Cell Therapies, apceth Biopharma, and more.
Benefits of partnering with a cell therapy CDMO include scalability, speed to market, access to technical expertise without overhead costs, and cost efficiencies. This report considers the role of cell therapy CDMOs, as well as the importance of in-house manufacturing at cell therapy companies worldwide.
This global strategic report provides detailed analysis of ten leading cell therapy companies worldwide, evaluating the strengths of each company, as well as identifying cell therapy products in development, manufacturing strategies, and partnerships. These companies include:
- Mesoblast Ltd.
- Asterias Biotherapeutics
- TiGenix NV
- Cynata Therapeutics
- Cytori Therapeutics
- Astellas Pharma (and Subsidiary Ocata Therapeutics)
- Gamida Cell Ltd.
- Pluristem Therapeutics
The report analyzes time frames for cell therapy product development, distribution channels, key trends and technologies impacting cell therapy manufacturing, cost control measures, and challenges and considerations affecting with cell therapy manufacturing.
It provides an overview of the regulatory environment affecting cell therapy manufacturing in key countries worldwide, evaluating the importance of the recent FDA guidelines for Human Cell and Tissue-based Products (HCT/Ps) and the 21st Century Cures Act, as well as accelerated pathways for cell therapy approvals in Japan, including the:
- Act on the Safety of Regenerative Medicine (Law No. 85/2013)
- Pharmaceuticals and Medical Device (PMD) Act (Law No. 84/2013)
BioInformant compiled this global strategic report using primary interviews with more than 50 individuals from across the cell therapy manufacturing industry, including representatives from:
- Gamida Cell Ltd. (Dr. Yael Margolin)
- Pluristem (Yaky Yanay, Yaron Ramati)
- Cynata Therapeutics (Dr. Paul Wotton)
- Accellta (Dr. Itzchak Angel and Eran Cohen)
- Stem Cell Medicine Ltd. (Dr. Frida Grynspan)
- Minerva Biotechnologies (Dr. Cynthia Bamdad)
- RoosterBio (Dr. Jon Rowley)
- Universal Cells (Gregory Block)
- Many More